Drug Interactions

Principles of Clinical Pharmacology

Volumn , Issue , 2007, Pages 229-247

  Robertson, Sarah ^a   Penzak, Scott ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956457358     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369417-1/50055-9     Document Type: Chapter

References (110)

1. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990, 264:2114.
2. Zimmermann M, Duruz H, Guinand O, et al. Torsades de pointes after treatment with terfenadine and keto-conazole. Eur Heart J 1992, 13:2214-2215.
3. Stephens M Introduction. Stephens' detection of new adverse drug reactions 2004, 481-494. John Wiley & Sons, Ltd, West Sussex, England. T. J, W. P (Eds.).
4. Stockley IH General considerations and an outline survey of some basic interaction mechanisms. Stockley's drug interactions 2002, 701. Pharmaceutical Press, London, England. S. IH (Ed.).
5. Dasgupta A, Okhuysen PC. Pharmacokinetic and other drug interactions in patients with AIDS. Ther Drug Monit 2001, 23:19-28.
6. Van Cleef GF, Fisher EJ, Polk RE. Drug interaction potential with inhibitors of HIV protease. Pharma-cotherapy 1997, 42:38-44.
7. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2004, 57:5889-5894.
8. Panel on clinical practices for treatment of HIV infection Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents 2004, Internet at. http://AIDSinfo.nih.gov.
9. Nomura A, Yasuda H, Katoh K, et al. Hydralazine and furosemide kinetics. Clin Pharmacol Ther 1982, 32:3296-3301.
10. Bohets H, Lavrijsen K, Hendrickx J, et al. Identi-fication of the cytochrome P450 enzymes involved in the metabolism of cisapride: In vitro studies of potential co-medication interactions. Br J Pharmacol 2000, 129:591-595.
11. Propulsid® cisapride [package insert] 2000, Janssen Pharmaceutica, Titusville, NJ.
12. Hochster H, Dieterich D, Bozzette S et al., Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS: An AIDS clinical.
13. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002, 72:395-405.
14. Shek A, Ferrill MJ. Statin-fibrate combination ther-apy. Ann Pharmacother 2001, 35:589-590.
15. Murdock DK, Murdock AK, Murdock RW, et al. Long-term safety and efficacy of combination gem-fibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J 1999, 138:35669-35675.
16. Gugler R, Allgayer H. Effects of antacids on the clinical pharmacokinetics of drugs: An update. Clin Pharmacokinet 1990, 18:554-565.
17. Wadhwa NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc 1987, 19:1343-1352.
18. Reyataz™ atazanavir [package insert] 2004, package insert issued 7, Bristol-Myers Squibb Company, Princeton, NJ.
19. Van der Meer JWM, Keuning JJ, Scheijgrond HW, et al. The influence of gastric acidity on the bioavail-ability of ketoconazole. J Antimicrob Chemother 1980, 6:273-282.
20. Sporanox R itraconazole [package insert] 2004, package insert revised 1, Janssen Pharmaceutical Products, L.P., Titusville, NJ.
21. Dear Health Care Provider letter 2004, Bristol-Myers Squibb Co.
22. Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol 1997, 37:5896-5901.
23. Polk RE. Drug-drug interactions with ciprofloxacin and other fluoroquinolones. Am J Med 1989, 87(suppl 5A):512-519.
24. Schentag JJ, Watson WA, Nix D, et al. Time depen-dent interactions between antacids and quinolone antibiotics. Clin Pharmacol 1988, 43:135.
25. D'Arcy PF, McElnay JC. Drug-antacid interac-tions: Assessment of clinical importance. Drug Intell Clin Pharm 1987, 21:273-287.
26. Neuvonen PJ. Interactions with the absorption of tetracyclines. Drugs 1976, 11:972-978.
27. Farmer JA, Gotto AM Jr. Antihyperlipidaemic agents. Drug interactions of clinical significance. Drug Safety 1994, 11:1611-1621.
28. Invirase R saquinavir mesylate [package insert] 2003, package insert revised 12, Roche Laboratories, Inc., Nutley, NJ.
29. Gupta SK, Benet LZ. Food increases the bioavailabil-ity of cyclosporine in healthy volunteers. Biopharm Drug Dispos 1989, 10:413-420.
30. Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting con-ditions with food and with antacids. Chest 1999, 155:663-671.
31. Peloquin CA, Namdar S, Dodge AA, Nix DE. Phar-macokinetics of isoniazid under fasting conditions with food and with antacids. Int J Tuberc Lung Dis 1999, 3:67-99.
32. Crixivan R indinavir sulfate [package insert] 2004, package insert revised 5, Merck & Co., Inc, Whitehouse Station, NJ.
33. Melander A, Danielson K, Hanson A, et al. Reduc-tion of isoniazid bioavailability in normal men by concomitant intake of food. Acta Med Scand 1976, 200:789-796.
34. Burman WJ, Gallicano K, Peloquin C. Compara-tive pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001, 40:2788-2790.
35. Trivedi S, Hyman J, Lichstein E. Clarithromycin and digoxin toxicity [letter]. Ann Intern Med 1998, 128:604.
36. Bizjak ED, Mauro VF. Digoxin-macrolide drug inter-action. Ann Pharmacother 1997, 31:1002-1003.
37. Lindenbaum J, Rund DG, Butler VP, Tse-Eng D, Saha JR. Inactivation of digoxin by the gut flora: Reversal by antibiotic therapy. N Engl J Med 1981, 305:1-88.
38. Berndt A, Gramatté T, Kirch W. Digoxin-erythromycin interaction: In vitro evidence for competition for intestinal P-glycoprotein. Eur J Pharmacol 1996, 50:538.
39. Wagasugi H, Yano I, Ito T, et al. Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein. Clin Pharmacol Ther 1998, 64:1-14.
40. Rengelshausen J, Göggelmann C, Burhenn J, et al. Contribution of increased oral bioavailability and reduced renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol 2003, 56:591-605.
41. Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orme ML, Rowe PH. Interindividual variation and drug interactions with hormonal steroid contracep-tives. Drugs 1981, 21:1553-1556.
42. Grimmer SFM, Allen WL, Back DJ, Breckenridge AM, Orme M, Tjia T. The effect of cotrimazole on oral contraceptive steroids in women. Contraception 1983, 28:121-126.
43. Friedman CI, Huneke AL, Kim MH, Powell J. The effect of ampicillin on oral contraceptive effective-ness. Obstet Gynecol 1980, 55:303-306.
44. Back DJ, Breckenridge AM, MacIver M, et al. The effect of ampicillin on oral contraceptive steroids in women. Br J Clin Pharmacol 1982, 14:1655-1667.
45. Shenfield GM. Oral contraceptives. Are drug interactions of clinical significance?. Drug Saf 1993, 9:685-691.
46. Dickinson BD, Altman RD, Neilsen NH, Sterling MI. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 2001, 98:908-917.
47. Shapiro LE, Shear NH. Drug interactions: Pro-teins pumps and P-450s. J Am Acad Dermatol 2002, 47:151-155.
48. Sansom LN, Evans AM. What is the true clinical significance of plasma protein binding displacement interactions?. Drug Saf 1995, 12:210-219.
49. Lewis DF. 57 varieties: The human cytochromes P450. Pharmacogenomics 1904, 5:1730-1733.
50. Thummel KE, Kunze KL, Shen DD Metabolically-based drug-drug interactions: Principles and mechanisms. Metabolic drug interactions 2000, 552-554. Lippincott Williams & Williams, Philadelphia. L. RH, T. KE, T. WF, H. PD, E. M (Eds.).
51. Bachmann KA, Ring BJ, Wrighton SA Drug-drug interactions and the cytochromes P450. Drug metabolizing enzymes: CYP450 and other enzymes in drug discovery and development 2003, 535-540. Marcel Dekker, Inc., New York. L. JS, O. S, F. MB (Eds.).
52. Dansette PM, Delaforge M, Sartori E, Beaune P, Jaouen M, Mansuy D. Drug interactions with macrolide antibiotics: Specificity of pseudo-suicide inhibition and induction of cytochrome P-450. Adv Exp Med Biol 1986, 197:76S-81S.
53. Collins JM Regulatory viewpoint: Prediction of drug interactions from in vitro studies. Metabolic drug interactions 2000, 135. Lippincott Williams & Wilkins, Philadelphia. L. RH, T. KE, T. WF, H. PD, E. M (Eds.).
54. Doherty MM, Charman WN. The mucosa of the small intestine. Clin Pharmacokinet 2002, 41:607-617.
55. Kupferschmidt HR, Ha WH, Ziegler PL, et al. Inter-action between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995, 58:45-54.
56. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin simvastatin acid and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998, 64:201-209.
57. Benton RE, Honig PK, Zamani K, et al. Grapefruit juice alters terfenadine pharmacokinetics resulting in pro-longation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996, 59:591-596.
58. Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991, 337:12-18.
59. Ducharme MP, Warbasse LH, Edwards DJ. Dispo-sition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995, 57:703-710.
60. Kufperschmidt HH, Fattinger KE, Ha HR, et al. Grape-fruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Phar-macol 1998, 45:93-97.
61. Bailey DG, Bend JR, Arnold MO, et al. Erythromycin-felodipine interaction: Magnitude mechanism and comparison with grapefruit juice. Clin Pharmacol Ther 1996, 60:327-341.
62. Kliewer SA, Moore JT, Wade L, et al. An orphan nuclear receptor activated by pregnane defines novel steroid signaling pathway. Cell 1998, 92:604.
63. Sueyoshi T, Kawamoto T, Zelko I, Honkakoshi P, Negishi M. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 1999, 274:1077-1079.
64. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998, 102:789-794.
65. Honkakoski P, Sueyoshi T, Negishi M. Drug-activated nuclear receptors CAR and PXR. Ann Med 2003, 35:538.
66. Lieber CS. Cytochrome P-4502E1: Its physiological and pathological role. Physiol Rev 1997, 77:123-128.
67. Handschin C, Meyer UA. Induction of drug metabolism: The role of nuclear receptors. Pharmacol Rev 2003, 55:32-38.
68. Christians U. Transport proteins and intestinal metabolism: P-glycoprotein and cytochrome P4503A. Ther Drug Monit 2004, 26:46-61.
69. Piscitelli SC, Burstein AH, Chaitt D, et al. Indi-navir concentrations St. John's wort. Lancet 2000, 355:53-59.
70. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet 2000, 355:33-37.
71. Johne A, Schmider J, Brockmoller J, et al. Decreased plasma levels of amitriptyline its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002, 22:43-48.
72. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003, 290:21-37.
73. Eich-Hochli D, Oppliger R, Golay KP, Baumann P, Eap CB. Methadone maintenance treatment St. John's wort3-a case report. Pharmacopsychiatry 2003, 36:853-860.
74. De Maat MM, Hoetelmans RM, Mathot RA, et al. Drug interaction between St John's wort and nevirapine. AIDS 2001, 15:467-484.
75. Sugimoto K, Ohmori M, Tsuruoka S, et al. Differ-ent effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001, 70:227-233.
76. Hebert MF, Park JM, Chen YL, Akhtar S, Larson AM. Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 2004, 44:305-318.
77. Hall SD, Wang Z, Huang SM, et al. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther 2003, 74:3-47.
78. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) fam-ily: An overview. Adv Drug Deliv Rev 2003, 55:311-336.
79. Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 2004, 43:155-162.
80. Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells express-ing cytochrome P-450 3A4. J Pharmacol Exp Ther 2000, 292:41-47.
81. Lin JH. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 2003, 55:235-253.
82. Benet LZ, Cummins CL, Wu CY. Transporter-enzyme interactions: Implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 2003, 4:20-28.
83. Lin JH, Yamazaki M. Role of P-glycoprotein in phar-macokinetics: Clinical implications. Clin Pharma-cokinet 2003, 42:477-483.
84. Durr D, Stieger B, Kullak-Ublick GA, et al. St. John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000, 68:383-388.
85. Zhao JY, Ikeguchi M, Eckersberg T, et al. Modulation of multi-drug resistance gene expression by dexam-ethasone in cultured hepatoma cells. Endocrinology 1993, 133:268-269.
86. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P450 3A coordinately upregulated these proteins in human colon carcinoma cells. Mol Pharmacol 1996, 49:485-491.
87. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999, 104:355-359.
88. Mordel A, Halkin H, Zulty L, et al. Quinidine enhances digitalis toxicity at therapeutic serum digoxin levels. Clin Pharmacol Ther 1993, 53:25-33.
89. Su FG, Huang JD. Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab Dispos 1996, 24:73-82.
90. Verschraagen M, Koks CHW, Schellens JHM, et al. P-glycoprotein system as a determinant of drug inter-actions: The case of digoxin-verapamil. Pharmacol Res 1999, 40:6043-6046.
91. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther. 2000, 68:1016-1023.
92. Rengelshausen J, Göggelmann C, Burhenne J, et al. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. J Clin Phar-macol 2003, 56:172-182.
93. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T. The organic anion transporter (OATP) family. Drug Metab Pharmacokin 2004, 19:171-179.
94. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral avail-ability of fexofenadine. Clin Pharmacol Ther 2002, 71:649-673.
95. Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 2005, 45:104-106.
96. Miyazaki H, Sekine T, Endou H. The multispe-cific organic anion transporter family: Properties and pharmacological significance. Trends Pharmacol Sci 2004, 25:547-548.
97. Khamdang S, Takeda M, Shimoda M, et al. Interac-tions of human-and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci 2004, 94:548-549.
98. Uwai Y, Saito H, Hashimoto Y, Inui KI. Inter-action transport of thiazide diuretics loop diuretics and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exper Ther 2000, 295:46-54.
99. Mulato AS, Ho ES, Cihlar T. Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exper Ther 2000, 295:1500-1504.
100. Lacy SA, Hitchcock MJM, Lee WA, Tellier P, Cundy KC. Effect of oral probenecid coadministra-tion on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol Sci 1998, 44:35-37.
101. Wang Y, Wei Y, Sawchuk RJ. Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. J Pharm Sci 1997, 86:420-421.
102. Proudfoot AT, Krenzelok EP, Vale JA. Position paper on urine alkalinization. J Toxicol Clin Toxicol. 2004, 42:518-524.
103. Hansten PD, Hayton WL. Effect of antacid and ascor-bic acid on serum salicylate concentrations. J Clin Pharmacol 1980, 20:89-94.
104. Stockley IH Antibacterial and anti-infective agent drug interactions. Stockley's drug interactions 2002, 525-535. Pharmaceutical Press, London. 6th ed. S. IH (Ed.).
105. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC. The effects of salicylate ibuprofen and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Phar-macol 1992, 42:3-29.
106. Dupuis LL, Koren G, Shore A, Silverman ED, Laxter RM. Methotrexate-nonsteroidal anti-inflammatory drug interaction in children with arthritis. J Rheumatol 1990, 1 7:553-576.
107. Stockley IH Lithium drug interactions. Stockley's drug interactions 2002, 310-318. Pharmaceutical Press, London. 6th ed. S. IH (Ed.).
108. Caraco Y, Sheller J, Wood AJJ. Pharmacogenetic determinants of codeine induction by rifampin: The impact on codeine's respiratory psychomotor and miotic effects. J Pharmacol Exper Ther 1997, 281:53-81.
109. CDER Guidance for Industry. Drug interaction/drug metabolism studies in the drug devel-opment process: Studies in vitro 1997, Internet at, Food and Drug Administration, Rockville, MD. http://www.fda.gov/cder/guidance/index.htm.
110. CDER Guidance for Industry vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling 1999, Internet at, Food and Drug Administration, Rockville, MD. http://www.fda.gov/cder/guidance/index.htm.